Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: Contemporary findings in real-life Danish patients

Journal of the American Heart Association

Volumn 6, Issue 2, 2017, Pages

  Lamberts, Morten ^a,b   Staerk, Laila ^a   Olesen, Jonas Bjerring ^a   Fosbøl, Emil Loldrup ^b,c   Hansen, Morten Lock ^d   Harboe, Louise ^f   Lefevre, Cinira ^f   Evans, David ^f   Gislason, Gunnar Hilmar ^a,c,e,g  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c Department of Cardiovascular Epidemiology and Research   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Anticoagulant; Atrial fibrillation; Bleeding

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

AGE; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DANISH CITIZEN; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENDER; HEMOPERICARDIUM; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTRAOCULAR HEMORRHAGE; KIDNEY HEMORRHAGE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RESPIRATORY TRACT HEMORRHAGE; URINARY TRACT HEMORRHAGE; BLOOD CLOTTING; BRAIN ISCHEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DENMARK; DRUG EFFECTS; FIBRINOLYTIC THERAPY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; BRAIN ISCHEMIA; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; THROMBOLYTIC THERAPY;

EID: 85015983099     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.004517     Document Type: Article

References (30)

1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, CaliffRM; Investigators RA. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; Committees A, Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
4. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest P. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141: e44S-e88S.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; Guidelines ESCCfP. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
6. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice G. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.
7. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490.
8. Kildemoes HW, Sorensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011;39:38-41.
9. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541-549.
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
11. Lamberts M, Lip GY, Hansen ML, Lindhardsen J, Olesen JB, Raunso J, Olsen AM, Andersen PK, Gerds TA, Fosbol EL, Torp-Pedersen C, Gislason GH. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med. 2014;161:690-698.
12. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, AhlehoffO, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
13. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, AhlehoffO, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9:1460-1467.
14. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, KrucoffMW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747.
15. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:480-486.
16. Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S. Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88-94.
17. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA, Kristensen SD, Rao SV, Verheugt FW, Widimsky P, Zeymer U, Collet JP. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32:1854-1864.
18. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, Becker RC, Singer DE, Halperin JL, Hankey GJ, Berkowitz SD, Fox KA, Patel MR. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66:2271-2281.
19. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157-164.
20. Loffredo L, Violi F, Perri L. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A metaanalysis of the interventional trials. Int J Cardiol. 2016;212:255-258.
21. Group EUCCS, Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerdts E, Foryst-Ludwig A, Maas AH, Kautzky-Willer A, Knappe-Wegner D, Kintscher U, Ladwig KH, Schenck-Gustafsson K, Stangl V. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37:24-34.
22. Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Kober L, Weeke P, Lip GY, Hansen ML. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3:e002758.
23. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264-2273.
24. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1-16.
25. Hernandez Madrid A, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, Todd D, Bongiorni MG, Sciaraffia E, Proclemer A, Cheggour S, Amara W, Blomstrom-Lundqvist C. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2016;18:463-467.
26. Heidbuchel H, Vrijens B. Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17:1317-1318.
27. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560-566.
28. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005;112:1736-1742.
29. Staerk L, Fosbol EL, Gadsboll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, Lip GY, Torp-Pedersen C, Gislason GH, Olesen JB. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011-2015 in Denmark. Sci Rep. 2016;6:31477.
30. AbuDagga A, Stephenson JJ, Fu AC, Kwong WJ, Tan H, Weintraub WS. Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res. 2014;14:310.